MOLECULAR PARTNERS AG
About MOLECULAR PARTNERS AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $153.8M
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $153.8M
- Shares outstanding
- 38.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 16, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 23% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MOLECULAR PARTNERS AG.
Write a review
News about MOLECULAR PARTNERS AG
News & sentiment via Polygon.io
